Treatment with Hizentra in patients with primary and secondary immunodeficiencies: a real-life, non-interventional trial

BACKGROUND: Although Hizentra is indicated for immunoglobulin replacement therapy in patients with primary and secondary immunodeficiencies, phase III trials have focused on patients with primary immunodeficiencies. In this 9-month, real-life, prospective, non-interventional, longitudinal, multicent...

Descripción completa

Detalles Bibliográficos
Autores principales: Viallard, J. F., Agape, P., Barlogis, V., Cozon, G., Faure, C., Fouyssac, F., Gaud, C., Gourin, M. P., Hamidou, M., Hoarau, C., Husseini, F., Ojeda-Uribe, M., Pavic, M., Pellier, I., Perlat, A., Schleinitz, N., Slama, B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5041334/
https://www.ncbi.nlm.nih.gov/pubmed/27687879
http://dx.doi.org/10.1186/s12865-016-0169-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5041334/
https://www.ncbi.nlm.nih.gov/pubmed/27687879
http://dx.doi.org/10.1186/s12865-016-0169-5

Ejemplares similares